Stockreport

Fennec Pharmaceuticals Announces Positive Topline Results From Investigator-Initiated Clinical Study of PEDMARK® in Japan to Reduce Cisplatin-Induced Hearing Loss

Fennec Pharmaceuticals Inc.  (FENC) 
Last fennec pharmaceuticals inc. earnings: 11/12 06:00 am Check Earnings Report
US:NASDAQ Investor Relations: investors.fennecpharma.com/investor-relations
PDF – Study, Which Enrolled 27 Patients, Met Primary Endpoint with a Significant Reduction in Hearing Loss in 3-18 Year Old Patients who Received PEDMARK® when Compared with [Read more]